Myovant, Sumitomo Call Alleged Skadden Conflict Public Info

By Katryna Perera · November 2, 2023, 4:49 PM EDT

Executives of Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have urged a New York federal judge to toss a proposed class action claiming the companies' merger was undervalued because lawyers...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Zappia v. Myovant Sciences Ltd. et al

Case Number

1:23-cv-08097

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

September 13, 2023